Clinical Pharmacokinetics

, Volume 33, Issue 1, pp 7–17 | Cite as

Clinical Pharmacokinetics of Mifepristone

  • Oskari HeikinheimoEmail author
Review Article Drug Disposition


Mifepristone is a steroidal antiprogestin and antiglucocorticoid acting at the receptor level. The aromatic dimethylaminophenyl side chain in position 11 of the steroid structure is essential for the antagonistic properties of mifepristone.

The pharmacokinetics of mifepristone are characterised by rapid absorption, a long half-life of 25 to 30 hours and micromolar serum concentrations following ingestion of doses currently in clinical use. The serum transport protein α1-acid glycoprotein (AAG) regulates the serum kinetics of mifepristone. Binding to AAG limits the tissue availability of mifepristone, explaining the low metabolic clearance rate of 0.55 L/kg/day and the low volume of distribution of mifepristone. Also, similar serum concentrations of mifepristone following ingestion of single doses exceeding 100mg can be explained by saturation of the binding capacity of serum AAG. Following oral intake, mifepristone is extensively metabolised by demethylation and hydroxylation, the initial metabolic steps are catalysed by the cytochrome P450 (CYP) enzyme CYP3A4.

The 3 most proximal metabolites, namely the monodemethylated, didemethylated and hydroxylated metabolites of mifepristone, all retain considerable affinity toward the human progesterone and glucocorticoid receptors; in addition, the serum concentrations of these 3 metabolites are in a similar range as those of the parent drug. Thus, the combined pool of mifepristone, as well as that of the metabolites, seems responsible for the biological actions of mifepristone.

Combination therapy with mifepristone and low dose prostaglandin is currently in clinical use for termination of early pregnancy in China, France, Sweden and the UK. The combined regimen is well tolerated and highly efficacious with a 95% rate of complete pregnancy terminations. Recent clinical studies on pregnancy termination have focused on dose optimisation of mifepristone and evaluation of the orally active prostaglandin derivative misoprostol. In addition, several other indications for the clinical use of mifepristone, such as induction of labour, contraception, as well as treatment of various hormone dependent disorders, are emerging.

The major obstacles currently inhibiting further evaluation and distribution of mifepristone are political rather than clinical. However, it is hoped that the eventual introduction of new antiprogesterone molecules by several manufacturers will enhance the availability of this important class of new drugs.


Endometriosis Early Pregnancy Misoprostol Mifepristone Medical Abortion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Salmon J, Mouren M. Radioimmunoassay of RU 486. In: Baulieu E-E, Shegal S, editors. The antiprogestin steroid RU 486 and human fertility control. New York: Plenum Press, 1985: 99–101CrossRefGoogle Scholar
  2. 2.
    Kawai S, Lynnette K, Nieman DD, et al. Pharmacokinetic properties of the antiglucocorticoid and antiprogesterone steroid RU 486 in man. J Pharmacol Exp Ther 1987; 241(2): 401–6PubMedGoogle Scholar
  3. 3.
    Földesi I, Falkay G, Kovács L. Determination of RU486 (Mifepristone) in blood by radioreceptorassay: a pharmacokinetic study. Contraception 1996; 54: 27–32PubMedCrossRefGoogle Scholar
  4. 4.
    Swahn ML, Wang G, Aedo AR, et al. Plasma levels of antiprogestin RU 486 following oral administration to non-pregnant and early pregnant women. Contraception 1986 Nov; 34(5): 469–81PubMedCrossRefGoogle Scholar
  5. 5.
    Heikinheimo O, Tevilin M, Shoupe D, et al. Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography. Contraception 1986 Dec; 34(6): 613–23PubMedCrossRefGoogle Scholar
  6. 6.
    Chang-hai H, Yong-en S, Zhi-hou Y, et al. Pharmacokinetic study of orally administered RU 486 in non-pregnant women. Contraception 1989 Oct; 40(4): 449–60CrossRefGoogle Scholar
  7. 7.
    Heikinheimo O, Kontula K, Croxatto H, et al. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. J Steroid Biochem 1987a; 26(2): 279–84PubMedCrossRefGoogle Scholar
  8. 8.
    Kekkonen R, Heikinheimo O, Mandelin E, et al. Pharmacokinetics of mifepristone after low oral doses. Contraception 1996; 54: 229–34PubMedCrossRefGoogle Scholar
  9. 9.
    Heikinheimo O, Lähteenmäki P, Koivunen E, et al. Metabolism and serum binding of RU 486 in women after various single doses. Hum Reprod 1987; 2: 379–85PubMedGoogle Scholar
  10. 10.
    Deraedt R, Bonnat C, Busigny M, et al. Pharmacokinetics of RU 486. Baulieu E-E, Shegal S, editors. The antiprogestin steroid RU 486 and human fertility control. New York: Plenum Press, 1985: 103–22CrossRefGoogle Scholar
  11. 11.
    Heikinheimo O, Croxatto H, Salvatierra A, et al. Intravaginal administration of RU486 in humans and rats: inadequate absorption in humans. Hum Reprod 1987; 2: 645–8PubMedGoogle Scholar
  12. 12.
    Heikinheimo O. Pharmacokinetics of the antiprogesterone RU486 in women during multiple dose administration. J Steroid Biochem 1989: 32: 21–5PubMedCrossRefGoogle Scholar
  13. 13.
    Heikinheimo O, Ranta S, Grunberg S, et al. Alterations in the pituitary-thyroid and pituitary-adrenal axes — consequences of long-term mifepristone treatment. Metabolism 1997; 46: 292–9PubMedCrossRefGoogle Scholar
  14. 14.
    Moguilewsky M, Philibert D. Biochemical profile of RU 486. In: Baulieu E-E, Shegal S, editors. The antiprogestin steroid RU 486 and human fertility control. New York: Plenum Press, 1985: 87–97CrossRefGoogle Scholar
  15. 15.
    Birgerson L. Termination of early human pregnancy with antiprogestational agents [dissertation]. Uppsala,: University of Uppsala, 1990Google Scholar
  16. 16.
    Grimaldi B, Barre J, Tillement J-P Les rôles respectifs des liasons aux protéines sanguines et tissulaires de la mifépristone (RU486) dans sa distribution quantitative dans l’organisme. C R Acad Sci Paris 1992; t.315, Série III: 93–9PubMedGoogle Scholar
  17. 17.
    Heikinheimo O, Haukkamaa M, Lähteenmäki P. Distribution of RU 486 and its demethylated metabolites in human. J Clin Endocr Metab 1989: 68: 270–5PubMedCrossRefGoogle Scholar
  18. 18.
    Liu JH, Garzo VG, Yen SSC. Pharmacodynamics of the antiprogesterone RU486 in women after oral administation. Fertil Steril 1988 Aug; 50(2): 245–9PubMedGoogle Scholar
  19. 19.
    Jang GR, Wrighton SA, Benet LZ. Identification of CYP3A4 as the principal enzyme catalyzing mifepristone (RU 486) oxidation in human liver microsomes. Biochem Pharmacol 1996; 52: 753–61PubMedCrossRefGoogle Scholar
  20. 20.
    Shi Y, Ye Z, He C, et al. Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women. Contraception 1993 Aug; 48: 133–49PubMedCrossRefGoogle Scholar
  21. 21.
    Guiochon-Mantel A, Loosfelt H, Ragot T, et al. Receptors bound to antiprogestin form abortive complexes with hormone responsive elements. Nature 1988; 336: 695–8PubMedCrossRefGoogle Scholar
  22. 22.
    Koering M, Healy D, Hodgen G. Morphologic response of endometrium to a progesterone receptor antagonist, RU486, in monkeys. Fertil Steril 1986; 45: 280–7PubMedGoogle Scholar
  23. 23.
    Sitruk-Ware R, Thalabard JC, Plunkett T. The use of the antiprogestin RU486 (mifepristone). Contraception 1990; 41: 221–43PubMedCrossRefGoogle Scholar
  24. 24.
    Csapo A, Pulkkinen M. Indispensability of the human corpus luteum in the maintenance of early pregnancy, luteectomy evidence. Obstet Gynecol Surv 1978; 33: 69–81PubMedCrossRefGoogle Scholar
  25. 25.
    Smith S, Kelly R. The effect of the antiprogeestins RU 486 and ZK 98734 on the synthesis and metabolism of prostaglandins F2a and E2 in separated cells from early human decidua. J Clin Endocrinol Metab 1987; 65: 527–34PubMedCrossRefGoogle Scholar
  26. 26.
    Norman J, Kelly R, Baird D. Uterine activity and decidual prostaglandin production in women in early pregnancy in response to mifepristone with or without indomethacin in vivo. Hum Reprod 1991; 6: 740–4PubMedGoogle Scholar
  27. 27.
    Cheng L, Kelly R, Thong K, et al. The effects of mifepristone (RU486) on prostaglandin dehydrogenase in decidual and chorionic tissue in early pregnancy. Hum Reprod 1993; 8: 705–9PubMedGoogle Scholar
  28. 28.
    Lefebvre Y, Proulx L, Elie R, et al. The effects of RU486 on cervical ripening. Am J Obstet Gynecol 1990; 162: 61–5PubMedGoogle Scholar
  29. 29.
    Birgerson L, Odlind V. The antiprogestational agent RU 486 as an abortifacient in early human pregnancy: a comparison of three dose regimens. Contraception 1988; 38: 391–400PubMedCrossRefGoogle Scholar
  30. 30.
    Heikinheimo O, Ylikorkala O, Turpeinen U, et al. Pharmacokinetics of the antiprogesterone RU486: no correlation to clinical performance of RU486. Acta Endocrinol 1990; 123: 298–304PubMedGoogle Scholar
  31. 31.
    Swahn ML, Bygdeman M. The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br J Obstet Gynecol 1988; 95: 126–34CrossRefGoogle Scholar
  32. 32.
    Cameron I, Michie A, Baird D. Therapeutic abortion in early pregnancy with antiprogestogen alone or in combination with prostaglandin analogue (Gemeprost). Contraception 1986; 34: 459–68PubMedCrossRefGoogle Scholar
  33. 33.
    World Health Organization Task Force on Post-ovulatory Methods of Fertility Regulation. Termination of pregnancy with reduced doses of mifepristone. BMJ 1993; 307: 532–7CrossRefGoogle Scholar
  34. 34.
    Peyron R, Aubény E, Targosz V, et al. Early termination of pregnancy with mifepristone (RU 486) and orally active prostaglandin misoprostol. N Engl J Med 1993; 328: 1509–13PubMedCrossRefGoogle Scholar
  35. 35.
    McKinley C, Thong K, Baird D. The effect of dose of mifepristone and gestation on the efficacy of medical abortion with mifepristone and misoprostol. Hum Reprod 1993; 9: 1502–5Google Scholar
  36. 36.
    Webster D, Penney GC, Templeton A, et al. A comparison of 600 and 200mg mifepristone prior to second trimester abortion with the prostaglandin misoprostol. Br J Obstet Gynecol 1996 Jul; 103: 706–9CrossRefGoogle Scholar
  37. 37.
    Ulmann A, Silvestre L, Chemama L, et al. Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue. Acta Obstet Gynecol Scand 1992; 71: 278–83PubMedCrossRefGoogle Scholar
  38. 38.
    Rodger M, Baird D. Blood loss following induction of early abortion using mifepristone (RU486) and a prostaglandin analogue (Gemeprost). Contraception 1989; 40: 439–48PubMedCrossRefGoogle Scholar
  39. 39.
    Henshaw R, Naji S, Russell I, et al. A comparison of medical abortion with surgical vacuum aspiration: women’s preferences and acceptability of the treatment. BMJ 1993; 307: 714–7PubMedCrossRefGoogle Scholar
  40. 40.
    Hill N, Ferguson J, MacKenzie I. The efficacy of oral mifepristone (RU38486) with a prostaglandin E1 analog vaginal pessary for the termination of early pregnancy: complications and patient acceptability. Am J Obstet Gynecol 1990; 162: 414–7PubMedGoogle Scholar
  41. 41.
    Frydman R, Fernandez H, Pons J-C, et al. Mifepristone (RU486) and therapeutic late pregnancy termination: a double-blind study of two different doses. Hum Reprod 1988; 6: 803–6Google Scholar
  42. 42.
    Rodger M, Baird D. Pretreatment with mifepristone (RU486) reduces interval between prostaglandin administration and expulsion in second trimester abortion. Br J Obstet Gynecol 1990; 97: 41–5CrossRefGoogle Scholar
  43. 43.
    EI-Refaey H, Hinshaw K, Templeton A. The abortifacient effect of misoprostol in the second trimester: a randomized comparison with gemeprost in patients pre-treated with mifepristone (RU486). Hum Reprod 1993; 8(10): 1744–6Google Scholar
  44. 44.
    Frydman R, Lelaidier C, Baton-Saint-Mleux C, et al. Labor induction in women at term with mifepristone (RU486): a double-blind, randomized, placebo-controlled study. Obstet Gynecol 1992; 80: 972–5PubMedGoogle Scholar
  45. 45.
    Cabrol D, Dubois C, Cronje H, et al. Induction of labor with mifepristone (RU486) in intrauterine fetal death. Am J Obstet Gynecol 1990; 163: 540–2PubMedGoogle Scholar
  46. 46.
    Hill N, Selinger M, Ferguson J, et al. The placental transfer of mifepristone (RU486) during the second trimester and its influence upon maternal and fetal steroid concentrations. Br J Obstet Gynaecol 1990; 97: 406–11PubMedCrossRefGoogle Scholar
  47. 47.
    Luukkainen T, Heikinheimo O, Haukkamaa M, et al. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU486. Fertil Steril 1988; 49: 961–3PubMedGoogle Scholar
  48. 48.
    Kettel LM, Murphy AA, Mortola JF, et al. Endocrine responses to long-term administration of the antipregesterone RU 486 in patients with pelvic endometriosis. Fertil Steril 1991 Sep; 56(3): 402–7PubMedGoogle Scholar
  49. 49.
    Ledger W, Sweeting V, Hillier H, et al. Inhibition of ovulation by low-dose mifepristone (RU 486). Hum Reprod 1992; 7: 945–50PubMedGoogle Scholar
  50. 50.
    Croxatto H, Salvatierra AM, Croxatto H, et al. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum Reprod 1993; 8: 201–7PubMedGoogle Scholar
  51. 51.
    Batista M, Cartledge T, Zellmer A, et al. Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: a potential new contraceptive strategy. Am J Obstet Gynecol 1992; 167: 60–5PubMedGoogle Scholar
  52. 52.
    Gemzell-Danielsson K, Westlund P, Johannisson E, et al. Effect of low weekly doses of mifepristone on ovarian function and endometrial development. Hum Reprod 1996; 11: 256–64PubMedCrossRefGoogle Scholar
  53. 53.
    Couzinet B, Le Strat N, Silvestre L, et al. Late luteal administration of the antiprogesterone in normal women: effects on the menstrual cycle events and fertility control in a long-term study. Fertil Steril 1990; 54: 1039–44PubMedGoogle Scholar
  54. 54.
    Paris F, Henry-Suchet J, Tesquier L, et al. Intrérét d’un stéroide à action antiprogestérone dans le traitement de la grossesse extra-utérine. Rev Fr Gynacol Obstet 1986; 81: 33–5Google Scholar
  55. 55.
    Glasier A, Thong K, Dewar M, et al. Mifepristone (RU486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. N Engl J Med 1992; 327: 1041–4PubMedCrossRefGoogle Scholar
  56. 56.
    Webb A, Russell J, Elstein M. Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception. BMJ 1992; 305: 927–31PubMedCrossRefGoogle Scholar
  57. 57.
    Murphy A, Kettel M, Morales A, el al. Regression of uterine leiomyomata in response to the antiprogesterone RU486. J Clin Endocrinol Metab 1993; 76: 513–7PubMedCrossRefGoogle Scholar
  58. 58.
    Yen S. Use of antiprogestins in the management of endometriosis and leiomyoma. In: Donaldson M, Dorflinger L, Brown S, et al., editors. Clinical applications of mifepristone RU486 and other antiprogestins. Washington, DC: National Academy Press, 1993: 189–209Google Scholar
  59. 59.
    Bakker G, Setyono-Han B, Portengen H, et al. Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J Steroid Biochem Mol Biol 1990; 37: 789–94PubMedCrossRefGoogle Scholar
  60. 60.
    Perrault D, Eisenhauer EA, Pritchard KI, et al. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma — a national cancer institute of Canada clinical trials group study. J Clin Oncol 1996; 14: 2709–12PubMedGoogle Scholar
  61. 61.
    Grunberg S, Weiss M, Spitz I, et al. Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone. J Neurosurg 1991; 74: 861–6PubMedCrossRefGoogle Scholar
  62. 62.
    Bertagna X, Bertagna C, Luton J-P, et al. The new steroid analog RU 486 inhibits glucocorticoid action in man. Clin Endocrinol Metab 1984; 59(1): 25–8CrossRefGoogle Scholar
  63. 63.
    Gaillard RC, Riondel A, Muller AF, et al. RU 486: a steroid with antiglucocorticosteroid activity that only disinhibits the human pituitary-adrenal system at a specific time of day. Proc Natl Acad Sci USA 1984 Jun; 81: 3879–82PubMedCrossRefGoogle Scholar
  64. 64.
    Lamberts SWJ, Koper JW, de Jong FH. The endocrine effects of long-term treatment with mifepristone (RU 486). J Clin Endocrinol Metab 1991; 73(1): 187–91PubMedCrossRefGoogle Scholar
  65. 65.
    Nieman LK, Chrousos GP, Kellner C, et al. Successful treatment of Cushing’s syndrome with the glucocorticoid antagonist RU 486. J Clin Endocrinol Metab 1985; 61(3): 536–40PubMedCrossRefGoogle Scholar
  66. 66.
    Bertagna X, Bertagna C, Laudat MH, et al. Pituitary-adrenal response to the antiglucocorticoid action of RU 486 in Cushing’s syndrome. J Clin Endocrinol Metab 1986; 63: 639–42PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  1. 1.Steroid Research Laboratory, Departments of Biomedicine and Obstetrics and GynecologyUniversity of HelsinkiHelsinkiFinland

Personalised recommendations